Asia Pacific Cell And Gene Therapy Manufacturing Market Size & Outlook

The cell and gene therapy manufacturing market in Asia Pacific is expected to reach a projected revenue of US$ 8,538.1 million by 2030. A compound annual growth rate of 26% is expected of Asia Pacific cell and gene therapy manufacturing market from 2023 to 2030.
Revenue, 2022 (US$M)
$1,342.7
Forecast, 2030 (US$M)
$8,538.1
CAGR, 2023 - 2030
26%
Report Coverage
Asia Pacific

Asia Pacific cell and gene therapy manufacturing market, 2018-2030 (US$M)

Asia
Unlock Premium

Asia Pacific cell and gene therapy manufacturing market highlights

  • The Asia Pacific cell and gene therapy manufacturing market generated a revenue of USD 1,342.7 million in 2022.
  • The market is expected to grow at a CAGR of 26% from 2023 to 2030.
  • In terms of segment, cell therapy was the largest revenue generating therapy type in 2022.
  • Gene Therapy is the most lucrative therapy type segment registering the fastest growth during the forecast period.
  • Country-wise, China is expected to register the highest CAGR from 2023 to 2030.


Asia Pacific data book summary

Market revenue in 2022USD 1,342.7 million
Market revenue in 2030USD 8,538.1 million
Growth rate26% (CAGR from 2022 to 2030)
Largest segmentCell therapy
Fastest growing segmentGene Therapy
Historical data covered2018 - 2021
Base year for estimation2022
Forecast period covered2023 - 2030
Quantitative unitsRevenue in USD million
Market segmentationGene Therapy, Cell Therapy
Key market players worldwideLonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd


Other key industry trends

  • In terms of revenue, Asia Pacific region accounted for 18.4% of the global cell and gene therapy manufacturing market in 2022.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • North America is the fastest growing regional market and is projected to reach USD 23,532.7 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cell And Gene Therapy Manufacturing Market Scope

Cell and gene therapy manufacturing market segmentation & scope
Gene Therapy
Stem Cell Therapy
Non Stem Cell Therapy
Pre-commercial/ R&D Scale
Commercial Scale
Contract manufacturing
In house manufacturing
Cell Processing
Cell Banking
Process Development
Fill & Finish Operations
Analytical & Quality Testing
Raw Material Testing
Vector Production
Others
Acute Lymphoblastic Leukemia (ALL)
Inherited Retinal Disease
Malignancies
Musculoskeletal therapies
Autoimmune disorders
Dermatology
Large B-Cell Lymphoma
Spinal Muscular Atrophy (SMA)
Others

Cell And Gene Therapy Manufacturing Market Companies

Name Profile # Employees HQ Website

Asia Pacific cell and gene therapy manufacturing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.


Cell therapy was the largest segment with a revenue share of 62.56% in 2022. Horizon Databook has segmented the Asia Pacific cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.


Asia Pacific is anticipated to be a growing market for cell and gene therapy manufacturing. The region accounted for a 26.0% revenue share in 2021 and is estimated to witness the fastest growth with a CAGR of 20.6% from 2021 to 2027.

Over the past several years, cell therapy market has gained momentum in Asia. This can be attributed to the establishment of accelerated approval pathways, growing private & government investments, and increasing healthcare needs.

Besides, unmet needs in personalized medicine are driving research for regenerative medicine technologies, in turn, leading to increase in demand for cell & gene therapy manufacturing services. Availability of funding grants, especially for cell & gene therapy manufacturing, is expected to further accelerate market growth.

Reasons to subscribe to Asia Pacific cell and gene therapy manufacturing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Asia Pacific cell and gene therapy manufacturing market databook

  • Our clientele includes a mix of cell and gene therapy manufacturing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific cell and gene therapy manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Asia Pacific cell and gene therapy manufacturing market size, by country, 2018-2030 (US$M)

Asia Pacific Cell And Gene Therapy Manufacturing Market Outlook Share, 2022 & 2030 (US$M)

Asia Pacific cell and gene therapy manufacturing market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more